RET Fusion

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Myeloid Leukemia, BCR-ABL1 Positive1
KIF5B::RET Fusion AND RET V804L	Dasatinib	Predictive	D	Supports Resistance	2	submitted	EID7515 In an in vitro kinase study, the recombinant RET V804L mutant kinase demonstrated resistance to dasatinib treatment at concentrations of 1μM and 10μM (activity %: 101 and 91) when compared to wild typ… (full text at CIViC) PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC	civic
Lung Adenocarcinoma2
KIF5B::RET Fusion	Everolimus + VandetanibCombination	Predictive	C	Supports Sensitivity Response	2	accepted	EID1622 Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion…

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Chronic Myeloid Leukemia, BCR-ABL1 Positive1

KIF5B::RET Fusion AND RET V804L

Dasatinib

Predictive

Supports Resistance

submitted

EID7515

In an in vitro kinase study, the recombinant RET V804L mutant kinase demonstrated resistance to dasatinib treatment at concentrations of 1μM and 10μM (activity %: 101 and 91) when compared to wild typ… (full text at CIViC)

PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC

civic

Lung Adenocarcinoma2

KIF5B::RET Fusion

Everolimus + VandetanibCombination

Predictive

Supports Sensitivity Response

accepted

EID1622

Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion…

Lung Non-Small Cell Carcinoma6
KIF5B::RET Fusion	Selpercatinib	Predictive	C	Supports Sensitivity Response	3	submitted	EID6948 A patient with a KIF5B::RET fusion positive NSCLC with brain metastases who had acquired resistance to alectinib experienced a dramatic response to the selective RET inhibitor selpercatinib (LOXO-292)… (full text at CIViC) PMID 29912274 · Subbiah et al., 2018 · Open in CIViC	civic
KIF5B::RET Fusion AND RET G810A	Lenvatinib + PonatinibSubstitutes	Predictive	D	Supports Sensitivity Response	3	submitted	EID4853 We established inducible KIF5B-RET transgenic mice and KIF5B-RET-dependent cell lines for preclinical modeling of KIF5B-RET-associated lung adenocarcinoma. By culturing cells with increasing concentra… (full text at CIViC) PMID 27496134 · Huang et al., 2016 · Open in CIViC	civic
KIF5B::RET Fusion AND RET G810A	Vandetanib	Predictive	D	Does Not Support Resistance	3	submitted	EID4852 We established inducible KIF5B-RET transgenic mice and KIF5B-RET-dependent cell lines for preclinical modeling of KIF5B-RET-associated lung adenocarcinoma. By culturing cells with increasing concentra… (full text at CIViC) PMID 27496134 · Huang et al., 2016 · Open in CIViC	civic
KIF5B::RET Fusion AND ( RET G810C OR RET G810S OR RET G810R )	Selpercatinib	Predictive	C	Supports Resistance	4	accepted	EID8195 A 61-year old patient with KIF5B-RET fusion positive NSCLC received clinical benefit from selpercatinib treatment initially. ctDNA surveillance showed the emergence of RET G810S 3 months after the sta… (full text at CIViC) PMID 31988000 · Solomon et al., 2020 · Open in CIViC	civic
KIF5B::RET Fusion AND RET G810S	Selpercatinib	Predictive	C	Supports Resistance	4	submitted	EID12496 A RET fusion-positive NSCLC patient who had been treated with multiple lines of chemotherapy and targeted therapies received selpercatinib. The patient initially tolerated selpercatinib achieving a sy… (full text at CIViC) PMID 31988000 · Solomon et al., 2020 · Open in CIViC	civic
KIF5B::RET Fusion AND RET V804L	Cabozantinib	Predictive	D	Does Not Support Resistance	3	submitted	EID4851 We established inducible KIF5B-RET transgenic mice and KIF5B-RET-dependent cell lines for preclinical modeling of KIF5B-RET-associated lung adenocarcinoma. By culturing cells with increasing concentra… (full text at CIViC) PMID 27496134 · Huang et al., 2016 · Open in CIViC	civic

Lung Non-Small Cell Carcinoma6

KIF5B::RET Fusion

Selpercatinib

Predictive

Supports Sensitivity Response

submitted

EID6948

A patient with a KIF5B::RET fusion positive NSCLC with brain metastases who had acquired resistance to alectinib experienced a dramatic response to the selective RET inhibitor selpercatinib (LOXO-292)… (full text at CIViC)

PMID 29912274 · Subbiah et al., 2018 · Open in CIViC

civic

KIF5B::RET Fusion AND RET G810A

Lenvatinib + PonatinibSubstitutes

Predictive

Supports Sensitivity Response

submitted

EID4853

We established inducible KIF5B-RET transgenic mice and KIF5B-RET-dependent cell lines for preclinical modeling of KIF5B-RET-associated lung adenocarcinoma. By culturing cells with increasing concentra… (full text at CIViC)

PMID 27496134 · Huang et al., 2016 · Open in CIViC

civic

KIF5B::RET Fusion AND RET G810A

Vandetanib

Predictive

Does Not Support Resistance

submitted

EID4852

PMID 27496134 · Huang et al., 2016 · Open in CIViC

civic

KIF5B::RET Fusion AND ( RET G810C OR RET G810S OR RET G810R )

Selpercatinib

Predictive

Supports Resistance

accepted

EID8195

A 61-year old patient with KIF5B-RET fusion positive NSCLC received clinical benefit from selpercatinib treatment initially. ctDNA surveillance showed the emergence of RET G810S 3 months after the sta… (full text at CIViC)

PMID 31988000 · Solomon et al., 2020 · Open in CIViC

civic

KIF5B::RET Fusion AND RET G810S

Selpercatinib

Predictive

Supports Resistance

submitted

EID12496

A RET fusion-positive NSCLC patient who had been treated with multiple lines of chemotherapy and targeted therapies received selpercatinib. The patient initially tolerated selpercatinib achieving a sy… (full text at CIViC)

PMID 31988000 · Solomon et al., 2020 · Open in CIViC

civic

KIF5B::RET Fusion AND RET V804L

Cabozantinib

Predictive

Does Not Support Resistance

submitted

EID4851

PMID 27496134 · Huang et al., 2016 · Open in CIViC

civic

Malignant Lung Neoplasm1
KIF5B::RET Fusion	Selpercatinib	Predictive	B	Supports Sensitivity Response	3	submitted	EID7067 In this phase 1 trial, 57 patients with RET fusion- or mutation positive cancers were treated in 7 dose levels. Among patients with RET-Fusion positive NSCLC, objective response rates were 65% (n = 17… (full text at CIViC) Open in CIViC	civic

Malignant Lung Neoplasm1

KIF5B::RET Fusion

Selpercatinib

Predictive

Supports Sensitivity Response

submitted

EID7067

In this phase 1 trial, 57 patients with RET fusion- or mutation positive cancers were treated in 7 dose levels. Among patients with RET-Fusion positive NSCLC, objective response rates were 65% (n = 17… (full text at CIViC)

Open in CIViC

civic

Malignant Neoplasm1
KIF5B::RET Fusion	Selpercatinib	Predictive	D	Supports Sensitivity Response	2	submitted	EID12814 Preclinical data demonstrated Ba/F3 cells transformed with KIF5B::RET were IL3 growth independent, and sensitive to selpercatinib with an IC50 of 17.5 +/- 0.7 nM, which the authors considered sensitiv… (full text at CIViC) PMID 37376747 · Szymczak et al., 2023 · Open in CIViC	civic

Malignant Neoplasm1

KIF5B::RET Fusion

Selpercatinib

Predictive

Supports Sensitivity Response

submitted

EID12814

Preclinical data demonstrated Ba/F3 cells transformed with KIF5B::RET were IL3 growth independent, and sensitive to selpercatinib with an IC50 of 17.5 +/- 0.7 nM, which the authors considered sensitiv… (full text at CIViC)

PMID 37376747 · Szymczak et al., 2023 · Open in CIViC

civic

Solid Neoplasm1
KIF5B::RET Fusion	Pralsetinib	Predictive	C	Supports Sensitivity Response	2	submitted	EID11265 In the phase 1/2 clinical trial NCT03037385, one arm assessed the therapeutic benefit of the selective RET inhibitor pralsetinib across a range RET fusion positive solid tumors, excluding NSCLC and th… (full text at CIViC) PMID 35962206 · Subbiah et al., 2022 · Open in CIViC	civic

Solid Neoplasm1

KIF5B::RET Fusion

Pralsetinib

Predictive

Supports Sensitivity Response

submitted

EID11265

In the phase 1/2 clinical trial NCT03037385, one arm assessed the therapeutic benefit of the selective RET inhibitor pralsetinib across a range RET fusion positive solid tumors, excluding NSCLC and th… (full text at CIViC)

PMID 35962206 · Subbiah et al., 2022 · Open in CIViC

civic

Evidence by cancer (12 items)

Clinical significance (0)